News >

FDA Grants Adjuvant Dabrafenib/Trametinib Breakthrough Designation for BRAF+ Melanoma

Jason Harris
Published: Monday, Oct 23, 2017

Samit Hirawat, executive vice president and head, Global Drug Development at Novartis Oncology
Samit Hirawat
The FDA has awarded the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) a breakthrough therapy designation for the adjuvant treatment of patients with stage III melanoma with a BRAF V600 mutation following complete resection.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x